Wyeth Premarin/Prempro Cardioprotection Claim On Hold Until 2005
Executive Summary
Wyeth-Ayerst's pursuit of a cardioprotection claim for conjugated estrogens is likely delayed until 2005-2007 following the negative outcome of the Heart and Estrogen/Progestin Replacement Study.
You may also be interested in...
WHI Premarin Data Will Not Affect Bazedoxifene Phase III Studies, Wyeth Says
The Women's Health Initiative hormone therapy safety findings will not affect the regulatory pathway for Wyeth's Phase III estrogen/SERM combination, VP-Investor Relations Justin Victoria said
WHI Premarin Data Will Not Affect Bazedoxifene Phase III Studies, Wyeth Says
The Women's Health Initiative hormone therapy safety findings will not affect the regulatory pathway for Wyeth's Phase III estrogen/SERM combination, VP-Investor Relations Justin Victoria said
Premarin WHI Results May Mean Additional Labeling Changes, FDA Says
FDA may request additional changes to the labeling of hormone replacement therapies based on the findings from the terminated Premarin arm of the Women's Health Initiative